CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 98 enrolled
Drug / intervention
S-648414 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04147715
NCT04147715Phase 1Completed

A Phase 1, Randomized, Double-Blind, Single-Ascending-Dose, and Food Effect Study to Assess the Safety, Tolerability, Ventricular Repolarization, and Pharmacokinetics of S-648414 in Healthy Adult Study Participants (Part 1); A Phase 1, Randomized, Double-Blind, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of S-648414 and A Drug-Drug Interaction Study With the CYP3A Substrate, Midazolam, in Healthy Adult Study Participants (Part 2)

Shionogi·interventional·Posted Nov 1, 2019·Updated Nov 1, 2021

In Brief

A Phase 1 clinical trial evaluating S-648414, Placebo, and 2 other interventions for Healthy Volunteer. Completed, enrolled 98 participants across 2 sites in 2 countries.

Detailed Summary

The primary objective of Part 1 of the study is to evaluate the safety and tolerability of S-648414 after administration of a single oral dose of S-648414 in healthy adult study participants. The primary objective of Part 2 is to evaluate the safety and tolerability of S-648414 after administration of multiple oral doses of S-648414 in healthy adult study participants. The primary objectives of Part 3 are evaluate the safety and tolerability of S-648414 after administration of multiple oral doses of S-648414 in healthy adult study participants, and to evaluate the effect of S-648414 on the pharmacokinetics (PK) of dolutegravir and the effect of dolutegravir on the PK of S-648414 in healthy adult study participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan, United States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 1, 2019
Enrollment StartOct 9, 2019
Primary CompletionSep 22, 2020
Study CompletionSep 29, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.7 years ago

Interventions

S-648414drug

Tablet for oral administration

Placebodrug

Tablet for oral administration

Midazolamdrug

Solution for oral administration

Dolutegravirdrug

Tablet for oral administration